Loading…

When CFSPID becomes CF

•There are no standardized protocols or predictors of reclassification from CFSPID to CF.•We report a case series of 10 children who reclassified.•The increase in sweat chloride concentration with age may be associated with risk of reclassification.•CFTR functional assay may supplement sweat chlorid...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2022-01, Vol.21 (1), p.e23-e27
Main Authors: Ginsburg, Daniella, Wee, Choo Phei, Reyes, Maria Carmen, Brewington, John J., Salinas, Danieli B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3
cites cdi_FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3
container_end_page e27
container_issue 1
container_start_page e23
container_title Journal of cystic fibrosis
container_volume 21
creator Ginsburg, Daniella
Wee, Choo Phei
Reyes, Maria Carmen
Brewington, John J.
Salinas, Danieli B.
description •There are no standardized protocols or predictors of reclassification from CFSPID to CF.•We report a case series of 10 children who reclassified.•The increase in sweat chloride concentration with age may be associated with risk of reclassification.•CFTR functional assay may supplement sweat chloride test in defining the diagnosis and potentially used for prognosis of CRMS/CFSPID children. There has been a growing number of infants identified as CRMS/CFSPID in countries applying genetic testing as part of cystic fibrosis (CF) newborn screening. Currently there are neither standardized protocols for follow up beyond infancy, nor established predictors to stratify this population as high or low risk of reclassification to CF or CFTR-related disorder. We report a series of 10 children who reclassified, including eight carrying CFTR variants of varying clinical consequence and seven with initial sweat chloride measurements
doi_str_mv 10.1016/j.jcf.2021.06.012
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2596014697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1569199321012960</els_id><sourcerecordid>2596014697</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3</originalsourceid><addsrcrecordid>eNp9kEFLAzEQRoMotlavghfp0cuuM8lussGTVKuFgoKKx5DNzuIu3W5NWsF_b0qrR08zA-_7YB5jFwgpAsrrNm1dnXLgmIJMAfkBG2KhRJIDwmHcc6kT1FoM2EkILQAqUMUxG4hM5VIWfMjO3z9oOZ5MX55nd-OSXN9RiOcpO6rtItDZfo7Y2_T-dfKYzJ8eZpPbeeKEluuEtERltXKCSigrkVte5YW2iFVZKkk1gNIy4-hIE1mbcZcRz9C6vOBSkRixq13vyvefGwpr0zXB0WJhl9RvguG5loCZ1CqiuEOd70PwVJuVbzrrvw2C2eowrYk6zFaHAWmijpi53Ndvyo6qv8Tv_xG42QEUn_xqyJvgGlo6qhpPbm2qvvmn_gfEWmyS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596014697</pqid></control><display><type>article</type><title>When CFSPID becomes CF</title><source>Elsevier</source><creator>Ginsburg, Daniella ; Wee, Choo Phei ; Reyes, Maria Carmen ; Brewington, John J. ; Salinas, Danieli B.</creator><creatorcontrib>Ginsburg, Daniella ; Wee, Choo Phei ; Reyes, Maria Carmen ; Brewington, John J. ; Salinas, Danieli B.</creatorcontrib><description>•There are no standardized protocols or predictors of reclassification from CFSPID to CF.•We report a case series of 10 children who reclassified.•The increase in sweat chloride concentration with age may be associated with risk of reclassification.•CFTR functional assay may supplement sweat chloride test in defining the diagnosis and potentially used for prognosis of CRMS/CFSPID children. There has been a growing number of infants identified as CRMS/CFSPID in countries applying genetic testing as part of cystic fibrosis (CF) newborn screening. Currently there are neither standardized protocols for follow up beyond infancy, nor established predictors to stratify this population as high or low risk of reclassification to CF or CFTR-related disorder. We report a series of 10 children who reclassified, including eight carrying CFTR variants of varying clinical consequence and seven with initial sweat chloride measurements &lt;30 mmol/L. The overall increase in sweat chloride concentration was 5.8 mmol/L/year. Pseudomonas aeruginosa was isolated from respiratory cultures in five subjects, and reclassification was aided by human nasal epithelial cultures in two cases. In this center's experience, 6% of all CRMS/CFSPID referrals reclassified to CF over a 12-year period. The rate of sweat chloride increase, genotype, and CFTR functional assay can potentially be used as prognostic tools in the CRMS/CFSPID population.</description><identifier>ISSN: 1569-1993</identifier><identifier>EISSN: 1873-5010</identifier><identifier>DOI: 10.1016/j.jcf.2021.06.012</identifier><identifier>PMID: 34756682</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>CFSPID ; Child ; Child, Preschool ; CRMS ; Cystic Fibrosis - diagnosis ; Cystic Fibrosis - genetics ; Cystic Fibrosis Transmembrane Conductance Regulator - genetics ; Diagnosis ; Disease Progression ; Female ; Genetic Testing - methods ; Humans ; Infant ; Infant, Newborn ; Male ; Neonatal Screening - methods ; newborn screening ; reclassification ; sweat chloride</subject><ispartof>Journal of cystic fibrosis, 2022-01, Vol.21 (1), p.e23-e27</ispartof><rights>2021 European Cystic Fibrosis Society</rights><rights>Copyright © 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3</citedby><cites>FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3</cites><orcidid>0000-0002-6743-0019</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34756682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ginsburg, Daniella</creatorcontrib><creatorcontrib>Wee, Choo Phei</creatorcontrib><creatorcontrib>Reyes, Maria Carmen</creatorcontrib><creatorcontrib>Brewington, John J.</creatorcontrib><creatorcontrib>Salinas, Danieli B.</creatorcontrib><title>When CFSPID becomes CF</title><title>Journal of cystic fibrosis</title><addtitle>J Cyst Fibros</addtitle><description>•There are no standardized protocols or predictors of reclassification from CFSPID to CF.•We report a case series of 10 children who reclassified.•The increase in sweat chloride concentration with age may be associated with risk of reclassification.•CFTR functional assay may supplement sweat chloride test in defining the diagnosis and potentially used for prognosis of CRMS/CFSPID children. There has been a growing number of infants identified as CRMS/CFSPID in countries applying genetic testing as part of cystic fibrosis (CF) newborn screening. Currently there are neither standardized protocols for follow up beyond infancy, nor established predictors to stratify this population as high or low risk of reclassification to CF or CFTR-related disorder. We report a series of 10 children who reclassified, including eight carrying CFTR variants of varying clinical consequence and seven with initial sweat chloride measurements &lt;30 mmol/L. The overall increase in sweat chloride concentration was 5.8 mmol/L/year. Pseudomonas aeruginosa was isolated from respiratory cultures in five subjects, and reclassification was aided by human nasal epithelial cultures in two cases. In this center's experience, 6% of all CRMS/CFSPID referrals reclassified to CF over a 12-year period. The rate of sweat chloride increase, genotype, and CFTR functional assay can potentially be used as prognostic tools in the CRMS/CFSPID population.</description><subject>CFSPID</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>CRMS</subject><subject>Cystic Fibrosis - diagnosis</subject><subject>Cystic Fibrosis - genetics</subject><subject>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Genetic Testing - methods</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Neonatal Screening - methods</subject><subject>newborn screening</subject><subject>reclassification</subject><subject>sweat chloride</subject><issn>1569-1993</issn><issn>1873-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLAzEQRoMotlavghfp0cuuM8lussGTVKuFgoKKx5DNzuIu3W5NWsF_b0qrR08zA-_7YB5jFwgpAsrrNm1dnXLgmIJMAfkBG2KhRJIDwmHcc6kT1FoM2EkILQAqUMUxG4hM5VIWfMjO3z9oOZ5MX55nd-OSXN9RiOcpO6rtItDZfo7Y2_T-dfKYzJ8eZpPbeeKEluuEtERltXKCSigrkVte5YW2iFVZKkk1gNIy4-hIE1mbcZcRz9C6vOBSkRixq13vyvefGwpr0zXB0WJhl9RvguG5loCZ1CqiuEOd70PwVJuVbzrrvw2C2eowrYk6zFaHAWmijpi53Ndvyo6qv8Tv_xG42QEUn_xqyJvgGlo6qhpPbm2qvvmn_gfEWmyS</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Ginsburg, Daniella</creator><creator>Wee, Choo Phei</creator><creator>Reyes, Maria Carmen</creator><creator>Brewington, John J.</creator><creator>Salinas, Danieli B.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6743-0019</orcidid></search><sort><creationdate>202201</creationdate><title>When CFSPID becomes CF</title><author>Ginsburg, Daniella ; Wee, Choo Phei ; Reyes, Maria Carmen ; Brewington, John J. ; Salinas, Danieli B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>CFSPID</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>CRMS</topic><topic>Cystic Fibrosis - diagnosis</topic><topic>Cystic Fibrosis - genetics</topic><topic>Cystic Fibrosis Transmembrane Conductance Regulator - genetics</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Genetic Testing - methods</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Neonatal Screening - methods</topic><topic>newborn screening</topic><topic>reclassification</topic><topic>sweat chloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ginsburg, Daniella</creatorcontrib><creatorcontrib>Wee, Choo Phei</creatorcontrib><creatorcontrib>Reyes, Maria Carmen</creatorcontrib><creatorcontrib>Brewington, John J.</creatorcontrib><creatorcontrib>Salinas, Danieli B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cystic fibrosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ginsburg, Daniella</au><au>Wee, Choo Phei</au><au>Reyes, Maria Carmen</au><au>Brewington, John J.</au><au>Salinas, Danieli B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>When CFSPID becomes CF</atitle><jtitle>Journal of cystic fibrosis</jtitle><addtitle>J Cyst Fibros</addtitle><date>2022-01</date><risdate>2022</risdate><volume>21</volume><issue>1</issue><spage>e23</spage><epage>e27</epage><pages>e23-e27</pages><issn>1569-1993</issn><eissn>1873-5010</eissn><abstract>•There are no standardized protocols or predictors of reclassification from CFSPID to CF.•We report a case series of 10 children who reclassified.•The increase in sweat chloride concentration with age may be associated with risk of reclassification.•CFTR functional assay may supplement sweat chloride test in defining the diagnosis and potentially used for prognosis of CRMS/CFSPID children. There has been a growing number of infants identified as CRMS/CFSPID in countries applying genetic testing as part of cystic fibrosis (CF) newborn screening. Currently there are neither standardized protocols for follow up beyond infancy, nor established predictors to stratify this population as high or low risk of reclassification to CF or CFTR-related disorder. We report a series of 10 children who reclassified, including eight carrying CFTR variants of varying clinical consequence and seven with initial sweat chloride measurements &lt;30 mmol/L. The overall increase in sweat chloride concentration was 5.8 mmol/L/year. Pseudomonas aeruginosa was isolated from respiratory cultures in five subjects, and reclassification was aided by human nasal epithelial cultures in two cases. In this center's experience, 6% of all CRMS/CFSPID referrals reclassified to CF over a 12-year period. The rate of sweat chloride increase, genotype, and CFTR functional assay can potentially be used as prognostic tools in the CRMS/CFSPID population.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34756682</pmid><doi>10.1016/j.jcf.2021.06.012</doi><orcidid>https://orcid.org/0000-0002-6743-0019</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1569-1993
ispartof Journal of cystic fibrosis, 2022-01, Vol.21 (1), p.e23-e27
issn 1569-1993
1873-5010
language eng
recordid cdi_proquest_miscellaneous_2596014697
source Elsevier
subjects CFSPID
Child
Child, Preschool
CRMS
Cystic Fibrosis - diagnosis
Cystic Fibrosis - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Diagnosis
Disease Progression
Female
Genetic Testing - methods
Humans
Infant
Infant, Newborn
Male
Neonatal Screening - methods
newborn screening
reclassification
sweat chloride
title When CFSPID becomes CF
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A34%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=When%20CFSPID%20becomes%20CF&rft.jtitle=Journal%20of%20cystic%20fibrosis&rft.au=Ginsburg,%20Daniella&rft.date=2022-01&rft.volume=21&rft.issue=1&rft.spage=e23&rft.epage=e27&rft.pages=e23-e27&rft.issn=1569-1993&rft.eissn=1873-5010&rft_id=info:doi/10.1016/j.jcf.2021.06.012&rft_dat=%3Cproquest_cross%3E2596014697%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-e9617a97c3eb0bd35a2d589a11dbb76ef00796421ce9eeaa42c4e241ac58267e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2596014697&rft_id=info:pmid/34756682&rfr_iscdi=true